Int'l : +1(646) 832-2886 | query@kbvresearch.com
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV Research, The Global Agentic AI in Pharmaceuticals Market size is expected to reach USD 2,418.1 Million by 2033, rising at a market growth of 37.3% CAGR during the forecast period.
The Global Agentic AI in Pharmaceuticals Market is experiencing rapid growth as pharmaceutical organizations increasingly adopt autonomous artificial intelligence systems capable of reasoning, adaptive learning, workflow orchestration, and real-time decision-making. Agentic AI is transforming traditional pharmaceutical development by enabling intelligent automation across drug discovery, clinical development, regulatory operations, pharmacovigilance, manufacturing optimization, and precision medicine initiatives. The growing demand for accelerated drug development, improved research productivity, enhanced regulatory compliance, and personalized therapeutic solutions is driving investments in advanced AI infrastructure and intelligent pharmaceutical ecosystems worldwide.
The Large Pharmaceutical Companies segment is leading the Global Agentic AI in Pharmaceuticals Market by End User in 2025; thereby, achieving a market value of USD 1,248.5 Million by 2033. Large pharmaceutical organizations continue to invest heavily in autonomous AI technologies to accelerate drug discovery, optimize clinical development, improve precision medicine programs, and enhance operational efficiency across pharmaceutical value chains. These companies are increasingly deploying agentic AI systems capable of autonomous reasoning, predictive modeling, workflow automation, and intelligent decision-making to support complex research and development activities. Growing investments in digital transformation and AI-driven innovation continue to strengthen segment growth.
The Cloud-Based segment is generating the maximum revenue share in the Global Agentic AI in Pharmaceuticals Market by Deployment Mode in 2025 and would continue to be a dominant segment till 2033, growing at a CAGR of 36.6% during the forecast period. Pharmaceutical companies are increasingly utilizing cloud-based platforms to support high-volume biomedical data processing, AI model training, and collaborative research activities across geographically dispersed teams. Cloud deployment enables scalable computing resources, cost-efficient infrastructure management, and faster deployment of advanced AI capabilities, making it an attractive option for pharmaceutical organizations seeking to accelerate innovation and research productivity.
The Clinical-Trial Design and Recruitment segment is generating the maximum revenue share in the Global Agentic AI in Pharmaceuticals Market by Application in 2025. Pharmaceutical organizations are increasingly leveraging agentic AI technologies to improve patient identification, recruitment optimization, trial design efficiency, and real-time trial management. Intelligent AI systems help streamline clinical development processes by analyzing large datasets, identifying eligible patient populations, optimizing study protocols, and supporting data-driven decision-making. The growing need to reduce trial timelines and improve success rates continues to drive adoption within this segment.
Full Report: https://www.kbvresearch.com/agentic-ai-in-pharmaceuticals-market/
The North America region dominated the Global Agentic AI in Pharmaceuticals Market by Region in 2025 and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1,065.6 Million by 2033. The Asia Pacific region is expected to witness a CAGR of 38.2% during (2026-2033). North America continues to lead the market due to strong pharmaceutical research and development investments, advanced AI infrastructure, extensive healthcare data availability, and widespread adoption of intelligent drug discovery platforms. Meanwhile, Asia Pacific is emerging as a high-growth market driven by expanding biotechnology research, increasing pharmaceutical manufacturing activities, and growing adoption of artificial intelligence technologies across major economies such as China, Japan, India, and South Korea.
By End User
By Deployment Mode
By Application
By Geography
Related Reports: